Key facts
- Halda Therapeutics’s last known valuation is $3.0B.
- It has raised $227.1M across 3 recorded rounds; the latest was Later Stage VC (Series B) ($126.5M) in Jul 2024.
- Notable investors include RA Capital Management, Connecticut Innovations, Canaan Partners, Frazier Healthcare Partners, Deep Track Capital — 14 tracked in total.
- Halda Therapeutics has filed 4 Form Ds with the SEC since 2019, most recently Aug 2024 ($126.5M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Halda Therapeutics
Funding rounds
3 roundsAbout Halda Therapeutics
Developer of a drug discovery platform designed to create therapeutic and precision medicines. The company's platform focuses on the discovery of medicines through the creation of novel therapies that modify disease-causing pathways, enabling healthcare providers to treat their patients based on a novel therapeutic modality.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Founded
- 2018
- Employees
- 46
- Website
- haldatx.com/
- Ownership
- Privately Held (backing)
Halda Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Halda Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Halda Therapeutics in its N-PORT filings yet. We sweep new filings monthly.